drugset / Trial / NCT05609045
A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster
Phase 1
Withdrawn
Wuhan Rhegen Biotechnology Co., Ltd.
Shenzhen Rhegen Biotechnology Co.,Ltd. · collabWuhan Recogen Biotechnology Co., Ltd. · collab
RandomizedSequentialQuadruple-blindPrevention
Summary
This is a randomized, double-blinded, placebo-controlled, dose-escalation study to valuate the safety and immunogenicity of RH109 as booster at 2 dose levels for ealthy adults who have received homologous or heterologous vaccination with 3 doses of COVID-19 inactivated and/or mRNA vaccine(s). The purpose of this study is to evaluate the safety and immunogenicity of RH109 as booster for healthy adults who have received homologous or heterologous vaccination with 3 doses of COVID-19 inactivated and/or mRNA vaccine(s).
Timeline
- Start
- 2023-06
- Primary completion
- 2023-08
- Completion
- 2023-12
Outcome
Outcome not reported
Stopped (Business): “business strategy adjustment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RH109 | Messenger RNA (mRNA) | — | — |